Zobrazeno 1 - 10
of 19
pro vyhledávání: '"E V, Kunder"'
Autor:
V. I. Mazurov, Sh. F. Erdes, I. Z. Gaydukova, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tsyupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, E. P. Ilivanova, A. V. Strelkova, V. V. Tyrenko, E. A. Mikhailova, A. V. Eremeeva
Publikováno v:
Современная ревматология, Vol 18, Iss 1, Pp 35-46 (2024)
The article presents the results of the three-year use of netakimab (NTK) in patients with ankylosing spondylitis (AS) as part of the phase III BCD-085-5/ASTERA study.Objective: to evaluate the long-term efficacy and safety of NTK over a three-year p
Externí odkaz:
https://doaj.org/article/35b1cb81150247aab4f58712cc2503b9
Autor:
T. V. Dubinina, A. B. Demina, E. M. Agafonova, Sh. F. Erdes, V. I. Mazurov, I. Z. Gaydukova, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tsyupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, V. V. Tyrenko, E. P. Ilivanova, A. V. Strelkova
Publikováno v:
Современная ревматология, Vol 17, Iss 6, Pp 52-58 (2023)
The article contains the data obtained during the 156-week follow-up of patients with ankylosing spondylitis (AS) in the ASTERA phase III study.Objective: to evaluate the effect impact of netakimab (NTK) on quality of life (QoL), back pain and work c
Externí odkaz:
https://doaj.org/article/21939fb7c39048f99cdce239380dea45
Autor:
V. I. Mazurov, M. A. Korolev, A. M. Prystrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, T. V. Plaksina, O. V. Antipova, D. G. Kretchikova, S. A. Smakotina, O. A. Tciupa, E. V. Puntus, T. A. Raskina, L. N. Shilova, T. V. Kropotina, O. B. Nesmeyanova, T. A. Popova, I. B. Vinogradova, Yu. N. Linkova, E. A. Dokukina, A. V. Plotnikova, P. S. Pukhtinskaia, A. V. Zinkina-Orikhan, A. V. Eremeeva, A. A. Lutckii
Publikováno v:
Современная ревматология, Vol 15, Iss 4, Pp 13-23 (2021)
Levilimab is anti-interleukin-6 receptor (IL6R) monoclonal antibody. The article presents data obtained during 24 weeks of the SOLAR phase III study.Objective: to confirm efficacy and safety of levilimab in combination with methotrexate (MTX) in pati
Externí odkaz:
https://doaj.org/article/e5807cdebb9f4373ba05f16f3438579e
Autor:
V. I. Mazurov, Sh. F. Erdes, I. Z. Gaydukova, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tsyupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, E. P. Ilivanova, A. V. Strelkova, A. V. Eremeeva, A. V. Zinkina-Orikhan
Publikováno v:
Современная ревматология, Vol 14, Iss 4, Pp 39-49 (2020)
Netakimab (NTK) is a humanized anti-interleukin-17A monoclonal antibody. To date, the drug has been approved to treat ankylosing spondylitis (AS), psoriatic arthritis, and plaque psoriasis. The paper gives the data obtained during 52-week follow-up o
Externí odkaz:
https://doaj.org/article/984673a23dad4308b93cdaa2748700af
Autor:
V. I. Mazurov, I. Z. Gaydukova, Sh. Erdes, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, T. V. Plaksina, P. A. Shesternya, T. V. Kropotina, O. V. Antipova, E. A. Smolyarchuk, O. A. Tciupa, D. I. Abdulganieva, S. A. Lapshina, D. G. Krechikova, I. G. Gordeev, O. B. Nesmeyanova, V. V. Tyrenko, E. P. Ilivanova, A. V. Strelkova, A. V. Eremeeva
Publikováno v:
Научно-практическая ревматология, Vol 58, Iss 4, Pp 376-386 (2020)
Netakimab (NTK) is a humanized monoclonal antibody targeting interleukin-17A.Objective. The main objective of BCD-085-5/ASTERA study was to prove superiority of NTK over placebo and assess its’ safety in patients with active AS.Subjects and methods
Externí odkaz:
https://doaj.org/article/7a1a0bd45df54172a1cd35efba011387
Autor:
Sh. Erdes, V. I. Mazurov, T. V. Dubinina, I. Z. Gaydukova, S. A. Lapshina, E. V. Zonova, D. G. Krechikova, T. V. Plaksina, O. V. Reshetko, S. A. Smakotina, P. А. Shesternya, I. G. Gordeev, T. G. Makulova, T. V. Povarova, T. A. Raskina, N. F. Soroka, A. M. Pristrom, E. V. Kunder, Yu. V. Usacheva, E. Yu. Stukalina, A. V. Eremeeva, E. V. Chernyaeva, R. A. Ivanov
Publikováno v:
Научно-практическая ревматология, Vol 57, Iss 6, Pp 668-677 (2019)
The paper presents the results of a double-blind (BCD-085-3/AILAS) phase II clinical trial of the original interleukin 17A (IL17A) inhibitor BCD-085 prescribed at different doses to patients with active ankylosing spondylitis (AS) and those of an ext
Externí odkaz:
https://doaj.org/article/d4904fdfb8d74d86b07500bfba5201ae
Autor:
A. M. Lila, V. I. Mazurov, E. V. Zonova, O. B. Nesmeyanova, T. V. Plaksina, D. G. Krechikova, O. V. Reshet’ko, L. N. Denisov, I. G. Gordeev, T. G. Pokrovskaya, O. V. Antipova, T. V. Kropotina, T. V. Povarova, P. A. Shesternya, E. N. Ushakova, N. F. Soroka, E. V. Kunder, A. V. Eremeeva, E. V. Chernyaeva, R. A. Ivanov, P. S. Pukhtinskaya
Publikováno v:
Научно-практическая ревматология, Vol 56, Iss 3, Pp 293-301 (2018)
The paper gives data on the clinical efficiency and safety profile of long-term use of the infliximab (INF) biosimilar BCD-055 versus the reference drug Remicade® (REM) in a population of patients with active ankylosing spondylitis (AS).Subjects and
Externí odkaz:
https://doaj.org/article/f2ab7d59b1704636a39acc713ecb7947
Autor:
E. L. Nasonov, E. V. Zonova, O. N. Ivanova, L. A. Knyazeva, V. I. Mazurov, R. R. Samigullina, I. M. Marusenko, O. B. Nesmeyanova, T. V. Plaksina, A. E. Sizikov, D. G. Krechikova, N. A. Petrochenkova, Yu. S. Shapovalova, N. S. Soroka, S. I. Pimanov, A. M. Pristrom, E. V. Kunder, E. V. Chernyaeva, A. V. Eremeeva, R. Ivanov
Publikováno v:
Научно-практическая ревматология, Vol 54, Iss 5, Pp 510-519 (2016)
The article considers the results of an international multicenter randomized clinical trial of the efficacy and safety of the brand-name drug rituximab (MabThera), a monoclonal antibody against CD20 antigen of B cells, and its biosimi-lar drug (Acell
Externí odkaz:
https://doaj.org/article/1851db3d61f34b5b9904808e9377604d
Autor:
E. V. Kunder
Publikováno v:
Медицинская иммунология, Vol 11, Iss 2-3, Pp 215-220 (2014)
Abstract. Polyclonal immunoglobulins G (subclasses 1, 2, 4) from sera of 255 patients and 69 healthy persons were studied by a combined approach using rivanol treatment and affinity chromatography. Enzymatic reactions were carried out according to th
Externí odkaz:
https://doaj.org/article/974523bd38b2423986ed96fea66706ee
Publikováno v:
Медицинская иммунология, Vol 14, Iss 4-5, Pp 337-346 (2014)
Abstract. A group of 266 patients with spondyloarthritidis and 69 healthy persons were included in our study. IgG preparations were isolated from blood sera by a combined rivanol/affine chromatography technique. Homogeneity of IgGs was tested by mean
Externí odkaz:
https://doaj.org/article/caad527e08484104bc691fd6822689ac